Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Public ClinicalTrials.gov record NCT03742895. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).
Study identification
- NCT ID
- NCT03742895
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 329 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 12, 2018 (Actual)
- Primary completion
- Aug 12, 2025 (Actual)
- Completion
- Jun 30, 2027 (Estimated)
- Last update posted
- Aug 14, 2026
2018 – 2027
United States locations
- U.S. sites
- 24
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Arizona Cancer Center - North Campus ( Site 0011) | Tucson | Arizona | 85719 | — |
| St Joseph Heritage Healthcare-Oncology ( Site 0056) | Fullerton | California | 92835 | — |
| Cedars Sinai Medical Center ( Site 0002) | Los Angeles | California | 90048 | — |
| UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0007) | San Francisco | California | 94158 | — |
| Rocky Mountain Regional Veterans Affairs Medical Center ( Site 0092) | Aurora | Colorado | 80045 | — |
| Winship Cancer Institute of Emory University ( Site 0025) | Atlanta | Georgia | 30322-1013 | — |
| Augusta University ( Site 0028) | Augusta | Georgia | 30912 | — |
| Markey Cancer Center ( Site 0018) | Lexington | Kentucky | 40536 | — |
| University of Maryland ( Site 0050) | Baltimore | Maryland | 21201 | — |
| Weinberg Cancer Institute at Franklin Square ( Site 0054) | Baltimore | Maryland | 21237 | — |
| University of Massachusetts ( Site 0017) | Worcester | Massachusetts | 01655 | — |
| Henry Ford Health System ( Site 0060) | Detroit | Michigan | 48202 | — |
| Cancer Partners of Nebraska ( Site 0051) | Lincoln | Nebraska | 68510 | — |
| Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0116) | Middletown | New Jersey | 07748 | — |
| Memorial Sloan-Kettering Cancer Center at West Harrison ( Site 0126) | Harrison | New York | 10604 | — |
| VA New York Harbor Healthcare System Manhattan ( Site 0094) | New York | New York | 10010 | — |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0057) | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center ( Site 0026) | New York | New York | 10065 | — |
| Southwestern Regional Medical Center, Inc. ( Site 0079) | Tulsa | Oklahoma | 74133 | — |
| Eastern Regional Medical Center, Inc. ( Site 0077) | Philadelphia | Pennsylvania | 19124 | — |
| Sanford Hematology Oncology-Sioux Falls SD ( Site 0012) | Sioux Falls | South Dakota | 57104 | — |
| Intermountain Healthcare ( Site 0043) | St. George | Utah | 84790 | — |
| Virginia Mason Medical Center ( Site 0052) | Seattle | Washington | 98101 | — |
| Veterans Affairs Puget Sound Health Care System [Seattle, WA] ( Site 0093) | Seattle | Washington | 98108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 106 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03742895, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 14, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03742895 live on ClinicalTrials.gov.